Current Report · Items 2.02, 9.01 · 8-K

Edgewise Therapeutics, Inc.

EWTXNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed Aug 6, 2026Accepted Aug 6, 2026, 8:05 AM EDTCIK 1710072Accession 0001104659-26-091671

Company context

Edgewise Therapeutics is a leading biopharmaceutical company focused on novel, muscle-targeted therapeutics. Leveraging its expertise in muscle biology and small molecule drug development, Edgewise is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy, heart failure and other serious cardiovascular and cardiometabolic conditions. To learn more, go to edgewisetx.com or follow Edgewise on LinkedIn, X, Facebook and Instagram.

Current securities

EWTXNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On August 6, 2026, Edgewise Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Filed exhibits (1)

EX-99.1 (by filename) tm2621653d1_ex99-1.htm

EX-99.1 2 tm2621653d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 News Release Edgewise Therapeutics Reports Second Quarter 2026 Financial Results - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) - - Completed sale of sevasemten and muscular dystrophy business to Servier for up to $2.65 billion in July 2026, strengthening the balance sheet, sharpening focus on the cardiovascular pipeline - BOULDER, Colo., Aug. 6, 2026 - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today reported financial results for the second quarter of 2026 and recent business highlights. “In the second quarter, Edgewise entered into a deal to sell sevasemten and our muscular dystrophy business to Servier. Our post-deal close financial position enhances our ability to advance EDG-7500 and our cardiovascular-focused pipeline toward important clinical and regulatory milestones as an independent company,” said Kevin Koch, Ph. D., President and Chief Executive Officer of Edgewise Therapeutics. “With positive Phase 2 CIRRUS…

Open exhibit ↗